Monitoring Response to Antiplatelet Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2006 by NHS Greater Glasgow and Clyde.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
NHS Greater Glasgow and Clyde
ClinicalTrials.gov Identifier:
NCT00327041
First received: May 15, 2006
Last updated: NA
Last verified: May 2006
History: No changes posted
  Purpose

Antiplatelet therapy plays a key role in the prevention of complications related to coronary angioplasty and stenting (PCI) including procedure related myocardial damage. Aspirin and clopidogrel are now universally prescribed in patients undergoing these procedures. However, loading and maintenance doses have not been established and variation in individual response is emerging. New tests to assess the effects of these drugs are being developed but have yet to be incorporated into routine clinical practice. We will assess the effects of aspirin and clopidogrel in a consecutive series of patients undergoing angioplasty using new assays which can be carried out at the bedside. We will compare the results with alternative laboratory based tests and look for an association between the results, peri-procedural myocardial necrosis and subsequent cardiovascular events.


Condition Phase
Coronary Stenosis
Coronary Thrombosis
Angioplasty, Balloon
Phase 4

Study Type: Observational
Official Title: Pilot Study Investigating the Use of a Variety of Assays to Detect Individual Response to Antiplatelet Therapy

Resource links provided by NLM:


Further study details as provided by NHS Greater Glasgow and Clyde:

Estimated Enrollment: 40
Study Start Date: January 2006
Estimated Study Completion Date: September 2006
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients aged 18-80 undergoing intended PCI for conventional indications. Informed written consent.

Exclusion Criteria:

Administration of GPIIbIIIa therapy prior to PCI, Oral anticoagulation, ticlopidine, dipyridamole, NSAID therapy, Pregnancy, Troponin I >0.2mcg/l on day of procedure, Chest pain in the 24 hrs prior to PCI. Anaemia (Hb<10g/dl). Platelet Count <150 or >450 x10^9/l, Personal or family history of bleeding disorder.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00327041

Contacts
Contact: Richard IS Good, BA MBBS MRCP 0044 141 211 6390 richard_good@hotmail.com
Contact: Keith G Oldroyd, MBChB, MD, FRCP 0044 141 211 2337 keith.Oldroyd@northglasgow.scot.nhs.uk

Locations
United Kingdom
Western Infirmary Recruiting
Glasgow, Scotland, United Kingdom, G11 6NT
Sponsors and Collaborators
NHS Greater Glasgow and Clyde
Investigators
Principal Investigator: Keith G Oldroyd, MBChB, MD, FRCP NHS Greater Glasgow and Clyde
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00327041     History of Changes
Other Study ID Numbers: rgoodtrial001
Study First Received: May 15, 2006
Last Updated: May 15, 2006
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by NHS Greater Glasgow and Clyde:
Aspirin
Clopidogrel
Balloon Angioplasty
Coronary Thrombosis

Additional relevant MeSH terms:
Coronary Thrombosis
Thrombosis
Coronary Stenosis
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Embolism and Thrombosis
Vascular Diseases

ClinicalTrials.gov processed this record on August 28, 2014